drugset / Trial / NCT05730673
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is aPhase II Study of Leronlimab (PRO 140) in combination with Regorafenib in Patients with CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)
Timeline
- Start
- 2022-09-20
- Primary completion
- 2023-05-27
- Completion
- 2023-08-10
Outcome
Outcome not reported
Stopped (Enrollment): “No participants enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leronlimab | Monoclonal antibody | 700 mg | Subcutaneous |
| Subject | Regorafenib | Small molecule | 80 mg | Oral |
| Subject | Regorafenib | Small molecule | 120 mg | Oral |
| Subject | Regorafenib | Small molecule | 160 mg | Oral |